Mildronate effects on cognitive function in elderly patients with arterial hypertension [PDF]
Кардиоваскулярная терапия и профилактика, 2012 Aim. To assess the effects of the “interval” (3 months of treatment, followed by treatment-free 3 months) and “persistent” (52 weeks) therapy with Mildronate (500 mg/d) in elderly patients with arterial hypertension (AH) and cognitive dysfunction ...
S. V. Nedogoda +8 more
doaj +4 more sources
EFFECTS OF THE DRUG MILDRONATE
, 2023 <p><i>Mildronate (3-(2,2,2-trimethylhydrazine) propionate; THP; MET-88; meldonium, quaterine) is an anti-ischemic drug developed in the Latvian Institute of Organic Synthesis.
Axmedov, Shamshod Jamshidovich
core +2 more sources
Mildronate in cardiology practice – current evidence, ongoing research, and future perspectives [PDF]
Кардиоваскулярная терапия и профилактика, 2012 The review discusses the benefits and various practical aspects of the new cardioprotector mildronate use in cardiology. The latest evidence on the mildronate role in complex therapy of patients with stable angina, or patients in the rehabilitation ...
V. P. Mikhin +3 more
doaj +2 more sources
The Vasorelaxant and Neuroprotective Effects of Mildronate in A Rabbit Subarachnoid Hemorrhage Model
Turkish Neurosurgery, 2020 AIM: To investigate the effects of an anti-ischemic agent, mildronate, on subarachnoid hemorrhage-induced vasospasm. MATERIAL and METHODS: Rabbits were randomly divided into four groups: control, subarachnoid hemorrhage (SAH), vehicle, and mildronate (n ...
Muhammed Taha, Eser +7 more
core +5 more sources
ANTIOXIDANT EFFECT OF MILDRONATE IN PATIENTS AFTER CORONARY REVASCULARISATION
Российский кардиологический журнал, 2009 The study included 149 patients, aged 41–75 years, with Functional Class II-III stable angina, who underwent coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI).
I. G. Gordeev +2 more
doaj +2 more sources
Experience with mildronate in cerebrovascular diseases
Медицинский совет, 2015 Over the past years, results of various clinical trials of drugs demonstrating their efficacy in the treatment of cardiovascular diseases have been published. The article discusses the results of clinical use of Mildronate (meldonium) in the treatment of
N. V. Pizova
core +3 more sources
Mildronate as a Regulator of Protein Expression in a Rat Model of Parkinson’s Disease
Medicina, 2011 Background. Mildronate (3-[2,2,2-trimethylhydrazinium] propionate dihydrate) traditionally is a well-known cardioprotective drug. However, our recent studies convincingly demonstrated its neuroprotective properties.
Ivars Kalvinsh +5 more
core +3 more sources
Neuroprotective effects of mildronate in a rat model of traumatic brain injury
Injury, 2019 Objective: Traumatic brain injury (TBI) is one of the most common preventable causes of mortality and morbidity. Inflammation, apoptosis, oxidative stress, and ischemia are some of the important pathophysiological mechanisms underlying neuronal loss ...
AKAKIN, DİLEK +3 more
core +4 more sources
Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease [PDF]
International Journal of Molecular Sciences, 2010 Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective
Vija Z. Klusa +23 more
core +4 more sources
Mildronate effectiveness in post-hospital rehabilitation of patients with myocardial infarction [PDF]
Кардиоваскулярная терапия и профилактика, 2012 Aim. To study the effects of mildronate, as a component of complex therapy, on left ventricular (LV) systolic and diastolic function and exercise capacity (EC) in myocardial infarction (MI) patients undergoing post-hospital rehabilitation.
V. P. Mikhin, O. N. Koltsova
doaj +2 more sources